1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Nephros, Inc.

Nephros, Inc.

NEPH
Nephros, Inc.US flagNASDAQ Capital Market
3.80
USD
+0.11
- -
41.25MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1
0.66
0.5
0.43
0.65
0.83
1.37
0.94
1.02
0.97
1.37
1.35
- -
1.8
Basic EPS, GAAP
0.76
-2.79
-0.82
-0.56
-0.14
-0.5
-0.45
-0.52
-0.41
-0.72
-0.15
0.01
- -
0.07
Free Cash Flow per Basic Share
-2.06
-0.94
-0.99
-0.4
-0.01
-0.53
-0.3
-0.79
-0.15
-0.33
0.07
-0.05
- -
-0.03
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-61.5
-43.13
-30.33
-22.27
-20.58
-18.13
-16.88
-14.52
-13.55
-13.87
-13.9
-13.71
- -
-13.46
Tangible Book Value per Share
-3.23
-2.78
0.31
-0.11
0.15
0.66
0.74
1.5
1.3
0.71
0.67
0.69
- -
0.89
Basic Weighted Avg Shares
2
3
4
5
6
7
8
9
10
10
10
11
- -
11
Sales/Revenue/Turnover
2
2
2
2
4
6
10
9
10
10
14
14
19
19
Operating Margin (%)
-190.63
-152.69
-175.98
-123.66
-58.44
-53.03
-32.04
-52.61
-31.83
-43.46
-11.19
0.04
6.1
3.54
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
1
-7
-3
-3
-1
-3
-3
-5
-4
-7
-2
- -
1
1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
16.85
1
1.52
Profit Margin (%)
75.98
-421.68
-158.85
-130.69
-21.24
-59.82
-33.09
-55.67
-40.2
-74.01
-11.06
0.52
6.35
4.06
Working Capital
-3
- -
2
- -
2
6
6
14
11
7
6
7
8
9
LT Debt
- -
- -
- -
1
1
1
2
2
- -
1
1
1
1
1
Total Equity
-4
-6
3
1
2
7
8
16
15
9
8
9
10
11
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
21.79
5.98
Return on Capital (%)
-1.65
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.05
-0.84
-0.55
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
50
52
32

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
11
11
11
Cash, Cash Equivalents & STI
5
5
4
Accounts Receivable, Net
3
2
4
Inventories
3
3
4
Total Current Liabilities
2
3
3
Payables & Accruals
2
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
45.23%
-5.88%
18.84%
Free Cash Flow
404.67%
-128.69%
-400.73%
Net Income, GAAP
168.13%
279.21%
1,513.51%
Sales/Revenue/Turnover
28.92%
18.37%
32.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4
3
4
4
14
2025
5
4
5
5
19
2026
5
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.03
0.02
0.03
0.01
2025
0.05
0.02
0.03
- -
- -
2026
0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Robert Banks
Full Time Employees
31
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
380 Lackawanna Place South Orange NJ United States of America 07079
IPO Date
Sep 21, 2004
CIK
0001196298
Website
nephros.com
Similar Companies
Yubo International Biotech Limited (YBGJ)
Spineway S.A. (ALSPW.PA)
Ekso Bionics Holdings, Inc. (EKSO)
PT Mark Dynamics Indonesia Tbk (MARK.JK)
Safilo Group S.p.A. (SAFLF)
Hologic, Inc. (HOLX)
Business
Nephros, Inc. (Nasdaq: NEPH) develops and sells advanced water filtration and purification solutions to medical and commercial markets in the United States; its core offerings include FDA Class II medical ultrafilters and microfilters for infection control that retain bacteria, viruses, endotoxins, Legionella, and other opportunistic waterborne pathogens using proprietary 0.005-micron and 0.1-micron hollow-fiber technology; dialysis water filtration products that purify water and bicarbonate concentrate to meet ANSI/AAMI/ISO standards for hemodialysis applications; and commercial filtration cartridges and drop-ins that improve taste, odor, reduce scale, soluble lead, cysts, particulates, heavy metals, chemical compounds, and biofilm in food service, hospitality, convenience stores, health care facilities, ice machines, beverage dispensers, and hydration stations. Founded in 1997 and headquartered in South Orange, New Jersey, the company operates through medical water filtration and commercial water filtration segments, serving hospitals, dialysis centers, laboratories, manufacturing, military, outdoor recreation, and institutional customers with point-of-use solutions, water system evaluations, ice machine audits, emergency response services, and water-quality education. Nephros recently launched its 19-Series PFAS filter in October 2025 for point-of-use reduction of per- and polyfluoroalkyl substances in potable water to address regulatory-driven chemical contamination concerns; introduced the HydraGuard 20-inch UltraFilter to expand into medical device manufacturing and pharmaceutical production markets compliant with ANSI/AAMI ST108 standards; achieved record third-quarter 2025 net revenue of $4.8 million, up 35% year-over-year with 51% programmatic revenue growth and fourth consecutive quarter of profitability; and reported year-to-date 2025 net revenue of $14.1 million, up 37%, with $1.1 million net income, $5.2 million cash reserves, and zero debt.

Company News

APIChat

  • seekingalpha.com

    Nephros, Inc. (NEPH) Q1 2026 Earnings Call Transcript

  • globenewswire.com

    Nephros Announces Financial Results for Quarter Ended March 31, 2026

  • prismmediawire.com

    �Nephros Schedules First Quarter 2026 Financial Results Conference Call

  • globenewswire.com

    Nephros Schedules First Quarter 2026 Financial Results Conference Call

  • prismmediawire.com

    Nephros Expands Strategic Focus in Greater New York Market with Dedicated Regional Leadership

  • globenewswire.com

    Nephros Expands Strategic Focus in Greater New York Market with Dedicated Regional Leadership

  • prismmediawire.com

    �­Nephros Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning Expertise

  • globenewswire.com

    Nephros Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning Expertise

  • defenseworld.net

    Reviewing Envista (NYSE:NVST) & Nephros (NASDAQ:NEPH)

  • seekingalpha.com

    Nephros, Inc. (NEPH) Q4 2025 Earnings Call Transcript

  • prismmediawire.com

    �­Nephros Announces Fourth Quarter and Record Fiscal Year 2025 Financial Results

  • globenewswire.com

    Nephros Announces Fourth Quarter and Record Fiscal Year 2025 Financial Results

  • prismmediawire.com

    �Nephros Schedules Fourth Quarter 2025 Financial Results Conference Call

  • globenewswire.com

    Nephros Schedules Fourth Quarter 2025 Financial Results Conference Call

  • defenseworld.net

    Analyzing CeriBell (NASDAQ:CBLL) & Nephros (NASDAQ:NEPH)

  • prismmediawire.com

    Nephros Expands into Puerto Rico to Deliver Differentiated Water Filtration Solutions Across Medical and Commercial Sectors

  • globenewswire.com

    Nephros Expands into Puerto Rico to Deliver Differentiated Water Filtration Solutions Across Medical and Commercial Sectors

  • defenseworld.net

    Head to Head Survey: Phibro Animal Health (NASDAQ:PAHC) vs. Nephros (NASDAQ:NEPH)

  • prismmediawire.com

    Nephros Launches the Nephros Water Institute to Lead National Water Safety Education

  • globenewswire.com

    Nephros Launches the Nephros Water Institute to Lead National Water Safety Education